Stay updated with breaking news from Peter Nussbaumer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With the funding, CasInvent Pharma will be strengthening its portfolio of CK1 inhibitors and progressing its lead compound to the development candidate status.
Credit: Hauke S. Hillen A newly developed compound starves cancer cells by attacking their "power plants" - the so-called mitochondria. The new compound prevents the genetic information within mitochondria from being read. Researchers from the Max Planck Institute for Biology of Ageing in Cologne, the Karolinska Institute in Stockholm and the University of Gothenburg report in their study that this compound could be used as a potential anti-tumour drug in the future; not only in mice but also in human patients. Mitochondria provide our cells with energy and cellular building blocks necessary ...
Researchers at Karolinska Institutet in Sweden report in the journal Nature that they have developed novel first-in-class inhibitors that compromise mitochondrial function in cancer cells. Treatment with the inhibitors stopped cancer cells from proliferating and reduced tumour growth in mice, without significantly affecting healthy cells. "We are excited to have shown that this novel principle for cancer treatment works in animal models and hopefully the inhibitors can now be developed further for anti-cancer treatment in humans," says Nils-Göran Larsson, professor at the Department of Medi...